OBJECTIVE: Transgender patients may seek hormone therapy to induce physical changes to simulate their expressed or experienced gender. However, many providers are uncomfortable prescribing transgender hormones due to fears over safety. The goal of this study was to determine if transgender hormone therapy with estrogen and spironolactone for male-to-female (MtF) patients or with testosterone for female-to-male (FtM) patients had adverse anthropomorphic or metabolic effects. METHODS: This retrospective chart review study analyzed changes over time for 33 MtF and 19 FtM endocrine clinic patients at an academic endocrine practice with follow-up for up to 18 months after hormone initiation. RESULTS: Compared to baseline labs obtained prior to the initiation of hormone therapy, significant changes for the MtF cohort included an increase in high-density lipoprotein (HDL) and decrease in creatinine; however, triglycerides did not show a statistically significant change. In the FtM cohort, there were significant increases in body mass index, creatinine, hemoglobin, and hematocrit. Although statistically significant, these changes were minimal for both cohorts. CONCLUSION: In our practice, hormone therapy was found to be safe in this retrospective study.
OBJECTIVE: Transgender patients may seek hormone therapy to induce physical changes to simulate their expressed or experienced gender. However, many providers are uncomfortable prescribing transgender hormones due to fears over safety. The goal of this study was to determine if transgender hormone therapy with estrogen and spironolactone for male-to-female (MtF) patients or with testosterone for female-to-male (FtM) patients had adverse anthropomorphic or metabolic effects. METHODS: This retrospective chart review study analyzed changes over time for 33 MtF and 19 FtM endocrine clinic patients at an academic endocrine practice with follow-up for up to 18 months after hormone initiation. RESULTS: Compared to baseline labs obtained prior to the initiation of hormone therapy, significant changes for the MtF cohort included an increase in high-density lipoprotein (HDL) and decrease in creatinine; however, triglycerides did not show a statistically significant change. In the FtM cohort, there were significant increases in body mass index, creatinine, hemoglobin, and hematocrit. Although statistically significant, these changes were minimal for both cohorts. CONCLUSION: In our practice, hormone therapy was found to be safe in this retrospective study.
Authors: Carla Pelusi; Antonietta Costantino; Valentina Martelli; Martina Lambertini; Alberto Bazzocchi; Federico Ponti; Giuseppe Battista; Stefano Venturoli; Maria C Meriggiola Journal: J Sex Med Date: 2014-09-24 Impact factor: 3.802
Authors: Tiffany K Roberts; Colleen S Kraft; Deborah French; Wuyang Ji; Alan H B Wu; Vin Tangpricha; Corinne R Fantz Journal: Am J Med Date: 2013-10-19 Impact factor: 4.965
Authors: Katrien Wierckx; Sven Mueller; Steven Weyers; Eva Van Caenegem; Greet Roef; Gunter Heylens; Guy T'Sjoen Journal: J Sex Med Date: 2012-08-20 Impact factor: 3.802
Authors: R Yahyaoui; I Esteva; J J Haro-Mora; M C Almaraz; S Morcillo; G Rojo-Martínez; J Martínez; J M Gómez-Zumaquero; I González; V Hernando; F Soriguer Journal: J Clin Endocrinol Metab Date: 2008-03-18 Impact factor: 5.958
Authors: Wylie C Hembree; Peggy Cohen-Kettenis; Henriette A Delemarre-van de Waal; Louis J Gooren; Walter J Meyer; Norman P Spack; Vin Tangpricha; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2009-06-09 Impact factor: 5.958
Authors: Anna Valentine; Shanlee Davis; Anna Furniss; Nadia Dowshen; Anne E Kazak; Christopher Lewis; Danielle F Loeb; Leena Nahata; Laura Pyle; Lisa M Schilling; Gina M Sequeira; Natalie Nokoff Journal: J Clin Endocrinol Metab Date: 2022-09-28 Impact factor: 6.134
Authors: Darius B Dawson; Donna L White; Elizabeth Chiao; Annette Walder; Jennifer R Kramer; Michael R Kauth; Jan A Lindsay Journal: Transgend Health Date: 2021-10-04
Authors: Kadden H Kothmann; Victoria Jacobsen; Emily Laffitte; Corinne Bromfield; Matthew Grizzaffi; Monica Jarboe; Andrea G Braundmeier-Fleming; Janice M Bahr; Romana A Nowak; Annie E Newell-Fugate Journal: Am J Physiol Endocrinol Metab Date: 2021-04-26 Impact factor: 5.900